Blenrep (belantamab mafadotin) for multiple myeloma — Dr. Jesus Berdeja | MCRT Webcast August 22

The promise of belantamab mafodotin for the treatment of multiple myelomaПодробнее

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее

Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple MyelomaПодробнее

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple MyelomaПодробнее

Know Your Myeloma Immunotherapy: Antibody Drug Conjugates with Dr. Jesus BerdejaПодробнее

All About BLENREP (Belantamab Mafodotin-blmf)Подробнее

MCRT San Diego 2020: Jesús Berdeja Presentation - ImmunotherapiesПодробнее

Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple MyelomaПодробнее

Treatment combinations being explored with belantamab mafodotin in multiple myelomaПодробнее

Dr. Berdeja on Treatment of Patients With Newly Diagnosed MyelomaПодробнее

DREAMM-2: Belantamab mafodotin for R/R myelomaПодробнее

Dr. Berdeja on Maintenance Therapy in Multiple MyelomaПодробнее

Managing belantamab mafodotin-associated corneal adverse events in multiple myelomaПодробнее

Dr. Berdeja on Updated Data With bb21217 in Multiple MyelomaПодробнее

Jesus Berdeja, MD, shares design and outcomes of the CARTITUDE-1 trial in multiple myeloma patientsПодробнее

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trialsПодробнее

The potential role of belantamab mafodotin in multiple myelomaПодробнее